Novocure reports positive phase 2 trial results for pancreatic cancer

March 26, 2026 7:00 AM

Novocure (NASDAQ: NVCR) announced that its Phase 2 PANOVA-4 clinical trial met its primary endpoint for treating metastatic pancreatic ductal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found